Investor Relations

Print   Email  
Stock price graph
     

Ocera is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet medical need. Ocera's lead program, OCR-002, is an ammonia scavenger designed to treat hyperammonemia (elevated ammonia in the blood) and associated hepatic encephalopathy, a complication of patients with liver cirrhosis.

View all »   RSSRecent Releases

Mar 2, 2015
Ocera Therapeutics to Announce Fourth Quarter and Full Year 2014 Financial Results

Feb 23, 2015
Ocera Therapeutics to Present at 35th Annual Cowen and Company Health Care Conference

View all »Events & Presentations

Mar 11, 2015 at 4:30 PM ET
Fourth Quarter and Full Year 2014 Earnings Call

Investors